Rolland, Y
Clinical trials have demonstrated weight loss ranging from approximately 10% with GLP-1 agents at weight management doses (e.g., semaglutide 2.4 mg in the STEP trials) to over 20% with tirzepatide at higher doses (SURMOUNT trials)
Besides, they have a higher chance encountering complications during pregnancy or even beyond, including miscarriage, GDM, preeclampsia, premature delivery, increased perinatal mortality and a higher risk of metabolic disorders for offspring [45, 46]
Indications & Cases: L-carnitine deficiency
Improves complexion, eliminates dullness and restores healthy glow
doi:10.1002/ijc.10404 Kuiper DR, Hoekstra HJ, Veth RP, Wobbes T